Baiji Shen Zhou (688235.SH) has a total operating income of 8.048 billion yuan in the first quarter, a year-on-year increase of 50.2%.

The Zhitong Finance and Economics APP reports that BeiGene (688235.SH) announced its main financial data for the first quarter of 2025. During the reporting period, the company achieved a total operating income of 8.048 billion yuan, a year-on-year increase of 50.2%, with product revenue at 7.985 billion yuan, a year-on-year increase of 49.9%. Operating profit and total profit turned from a loss to a profit. The growth in product revenue was mainly due to the sales growth of the company's self-developed product BeiYueZe (Zubutini capsules), as well as BeiZeAn (Terilizumab) and Anjin authorized products.